Pseudotype formation is a powerful tool for analysing mechanisms of virus neutralization and entry, since it allows for analysis of glycoprotein properties without the necessity for preparing recombinant genomes. Using recombinant vaccinia viruses, we prepared pseudotypes of La Crosse virus with recombinant glycoproteins cloned from the monoclonal antibody (MAb)-resistant variant V31. The resulting pseudotypes became partially resistant to MAb 807-31. Furthermore, when the V31 glycoproteins were incorporated into a second MAb-resistant variant (V33), the pseudotyped virus became sensitive to neutralization by the MAb (807-33) originally used in its selection. These results suggest a simple technique for the incorporation of glycoprotein mutations into bunyaviruses, allowing analysis of mechanisms of neutralization and other virus entry functions.
Pseudotype formation is a powerful tool for analysing mechanisms of virus neutralization and entry, since it allows for analysis of glycoprotein properties without the necessity for preparing recombinant genomes. Using recombinant vaccinia viruses, we prepared pseudotypes of La Crosse virus with recombinant glycoproteins cloned from the monoclonal antibody (MAb)-resistant variant V31. The resulting pseudotypes became partially resistant to MAb 807-31. Furthermore, when the V31 glycoproteins were incorporated into a second MAb-resistant variant (V33), the pseudotyped virus became sensitive to neutralization by the MAb (807-33) originally used in its selection. These results suggest a simple technique for the incorporation of glycoprotein mutations into bunyaviruses, allowing analysis of mechanisms of neutralization and other virus entry functions.
La Crosse virus (LAC) is a member of the California serogroup of the genus Bunyavirus of the family Bunyaviridae, and like all members of the family has a tri-segmented genome with segments designated L (large), M (medium) and S (small). The L RNA segment encodes the L or polymerase protein. The M segment encodes a single open reading frame that is processed into the two viral glycoproteins G1 and G2, as well as NSm -a non-structural protein of unknown function. The S segment encodes the nucleocapsid protein and another nonstructural protein (NSs) in overlapping reading frames (Elliott, 1990) .
The G1 and G2 glycoproteins of LAC have been expressed using vaccinia virus (VV) vectors. Several of the glycoprotein functions, such as targeting to the Golgi apparatus (a characteristic of bunyaviruses) and pH-dependent fusogenicity, are faithfully reproduced by the recombinant proteins (Bupp et Jacoby et al., 1993) . To determine whether the recombinant glycoproteins expressed from VV could also be functionally incorporated into LAC virions, we designed experiments in which a recombinant G1 protein with an antibody-resistant epitope was incorporated into either LAC or snowshoe hare virus (SSH), a related member of the California serogroup within the genus.
The construction of a VV expressing the LAC M RNA segment open reading frame (VV.ORF) has been described previously (Jacoby et al., 1993) . To prepare a recombinant virus containing an altered neutralization epitope, we used a monoclonal antibody (MAb)-resistant variant previously selected with MAb 807-31 (Gonza! lez- Scarano et al., 1982 ; Najjar et al., 1985) . To construct this virus (VV.V31), a translationally silent NcoI site was first introduced into a plasmid encoding the LAC M RNA (pM.ORF) at position 4085 in the antigenomic sense (Jacoby, 1992) , using PCR mutagenesis, changing the sequence in that region from TCTATGGCC to TCCATG-GCC. Another NcoI site (located in NSm) is present in the wildtype sequence at position 1046 in the antigenomic sense. To insert the resistant epitope, cellular RNA was extracted from BHK-21 cells infected with the MAb-resistant LAC variant V31, and amplified using reverse transcriptase followed by PCR with Vent DNA polymerase (New England Biolabs). The amplified region corresponded to a fragment from the NcoI site present in the wild-type sequence to the introduced NcoI site at position 4085 (located in the extracellular domain of G1). Replacement of the wild-type sequence by this fragment resulted in the replacement of a portion of NSm and the Nterminal 867 of 916 amino acids of the wild-type extracellular domain of the G1 protein with the corresponding V31 sequences. After this hybrid recombinant was constructed, a second, independent variant was isolated which was also resistant to MAb 807-31. The DNA sequence of the Nterminal fragment encoding the epitope for this antibody (K. Bupp, J. Fazakerley & F. Gonza! lez-Scarano, unpublished data) was determined for each variant. In both cases the glutamine at position 29 of the mature G1 sequence was the only amino acid mutated. In the variant described here the glutamine was changed to a glutamic acid. In the other, residue 29 was changed to an arginine.
The hybrid M segment cDNA was then removed from the plasmid by BamHI digestion, inserted into the BglII site of a Pseudotypes created using VV recombinants and either LAC or SSH were prepared as described in the text using either VV.V31 (which expresses G1 from a LAC variant resistant to MAb 807-31) or VV.ORF (which expresses the wild-type LAC G1). (a) Results with LAC are representative of five separate experiments. In all cases the differences in titres between the VV.V31-derived pseudotypes and the VV.ORF-derived control when treated with antibody were greater than 10-fold. The results shown employed ascites fluid diluted 1 : 100. (b) Results with SSH are representative of two separate experiments. The differences in titres between the VV.V31-derived pseudotypes and the VV.ORF-derived controls when treated with antibody were 5-fold and 10-fold for the two experiments. The results shown employed a hybridoma supernatant.
Co-infection (a)
LACjVV modified version of pSC11 (Chakrabarti et al., 1985) , and then recombined into VV as previously described (Jacoby et al., 1993) to prepare VV.V31. Immunofluorescence analysis of HeLa cells infected with VV.V31 showed that the G1 encoded by this construct was no longer recognized by MAb 807-31, although it was easily detected by a mixture of two other anti-G1 MAbs, 807-25 and 807-33 (data not shown) (Gonza! lezScarano et al., 1982 ; Najjar et al., 1985) . To prepare LAC pseudotypes, BHK-21 cells were grown in EMEM containing 10 % heat-inactivated FCS at 37 mC and when they had reached approximately 10-20 % confluence they were first infected with VV.V31 (m.o.i. l 10) for 4 h. This allowed accumulation of the recombinant protein before infection with wild-type LAC (m.o.i. l 1). The double infection proceeded for 18 h in the presence of 100 µg\ml rifampicin, which inhibits VV replication. The supernatant from the infected cells was removed and assayed for sensitivity to MAb 807-31.
Neutralization with 807-31 was tested by incubating serial 10-fold dilutions of virus supernatant (1 ml) with 100 µl of either an 807-31 hybridoma supernatant or a diluted 807-31 ascites fluid for 1 h at ambient temperature. This quantity of hybridoma supernatant decreases the titre of wild-type LAC by approximately 1000-fold. A 1 : 10 dilution of ascites fluid decreases the titre of LAC by approximately 10 000-fold. Plaques appearing at 10 −% after such treatment may be bona fide resistant variants. BHK-21 cells were then incubated with the virus-MAb mixture for 1 h at ambient temperature, and an agarose overlay was added after removal of the inoculum. The plaquing medium (EMEM with 2n5 % heat-inactivated FCS and rifampicin) did not contain antibody.
The results of one of several replicate experiments are shown in Table 1 and Fig. 1 , where the titres (represented as log "! ) were determined either in the presence or absence of the neutralizing MAb. The round plaque morphology observed was typical of LAC plaques rather than VV plaques, which are jagged on BHK-21 cells when rifampicin is left out of the plaquing medium. Approximately 1 % of the LAC population from the VV.V31\LAC co-infection was resistant to the MAb, whereas no resistant plaques were seen in the co-infection with the VV recombinant expressing the wild-type LAC glycoproteins. Increasing or decreasing the m.o.i. of the VV.V31 infection by 10-fold during the formation of pseudotypes did not have a significant influence on the amount of MAbresistant virus (data not shown).
Five separate supernatants containing pseudotypes were produced in this way using wild-type LAC. To ensure that the MAb-resistant plaques represented pseudotypes rather than MAb-resistant variants or other recombinants, three plaques were selected from the population resistant to 807-31, expanded, and their sensitivity to 807-31 tested. As expected, virus from all three plaques was sensitive to the antibody, confirming that the epitope had not been introduced into the LAC genome (not shown).
A similar procedure was then used to determine whether the LAC glycoproteins could be transiently introduced into SSH. The M segment ORFs of SSH and LAC are 89 % identical (Grady et al., 1987) Pseudotypes created using VV recombinants and MAb-resistant LAC variant V33 were prepared as described in the text using either VV.V31 (which expresses G1 from a LAC variant resistant to MAb 807-31) or VV.ORF (which expresses the wild-type LAC G1). Neutralizing MAbs 807-31 and 807-33 are directed against different epitopes on the G1 protein, and variant V33 was originally selected with MAb 807-33. There was no reduction in titre when the product of either co-infection was treated with MAb 807-33 alone (a). Table 2 (b) shows the results of experiments using the two MAbs (see text for details). Results are representative of two separate experiments. In both cases, the difference in titre between the VV.V31-derived pseudotypes and the VV.ORF-derived controls when treated with MAb 807-31 was greater than 10-fold. The further reduction in titre of VV.V31-derived pseudotypes seen on addition of MAb 807-33 was greater than 10-fold in both experiments.
V33jVV;V31 V33jVV;ORF Difference
No antibody 5n30* 5n59 k0n29 j807-33 5n08 5n17 0n09
No antibody 5n34* 5n49 k0n15 j807-31 3n85 1n48 2n37 j807-31 and 807-33 2n65 1n30 1n35 * Plaque titre (log "! ) when viral supernatants were titred with or without preincubation with hybridoma supernatants containing the indicated MAbs.
variable (Gonza! lez-Scarano et al., 1983) . Data from one of these experiments are presented in Table 1 . Again, there was evidence of resistance to neutralization by 807-31 in the supernatants of cells coinfected with VV.V31 and SSH in comparison with those coinfected with VV.ORF and SSH.
However, the efficiency of pseudotyping of SSH seems slightly lower than the efficiency of pseudotyping of LAC.
These results indicated that the requirements for incorporation of a recombinant glycoprotein onto a bunyavirion are not highly stringent and are in accord with data indicating that GGJ the spikes on the surface of the bunyavirus virion are not closely packed together (Hewlett & Chiu, 1991 ; Obijeski et al., 1976 ; Talmon et al., 1987) . Such an arrangement suggests that spikes originating from different bunyaviruses would not be mutually exclusive since requirements for stable lateral interactions would be minimal.
To determine whether incorporation of a recombinant glycoprotein by this technique could confer antibody sensitivity as well as resistance, we prepared VV.V31 pseudotypes with another MAb-resistant variant (V33 : resistant to MAb 807-33) instead of wild-type LAC (see Fig. 1 and Table 2 ). In these experiments we wanted to determine whether sensitivity to MAb 807-33 would be conferred by pseudotyping with the recombinant VV expressing the 807-31-resistant G1 (which binds MAb 807-33).
When the entire resultant population from the VV.V31\ V33 co-infection was tested for sensitivity to 807-33 alone, there was no detectable neutralization ( Fig. 1, Table 2 ). When we first neutralized the supernatant with MAb 807-31, we obtained a resistant subpopulation, consistent with previous experiments. Interestingly, this resistant population was mostly sensitive to 807-33, since a further 10-fold reduction in titre was seen when both antibodies were used (Fig. 1, Table 2 ). The additional reduction in titre with MAb 807-33 was similar to the reduction seen with wild-type LAC using the same amount of antibody (data not shown). The results of this experiment imply that binding and entry of the 807-31-resistant, 807-33-sensitive virions are mediated by the recombinant protein.
The mechanisms of neutralization of members of the Bunyaviridae by antibody have been examined previously (Green et al., 1992 ; Kingsford et al., 1991 ; Pekosz et al., 1995) , but not as quantitatively as with some other viruses (Icenogle et al., 1983 ; Taylor et al., 1987) . For example, poliovirus requires an average of four bound antibodies per virion (out of approximately 30 potential antibody-binding sites on each particle) to reduce the titre to 1\e of its original value (Icenogle et al., 1983) . For influenza virus, a similar reduction in titre requires the binding of an average of 70 of the approximately 700-1000 haemagglutinin spikes per virion by antibody (Taylor et al., 1987) . We have not quantified the proportion of recombinant protein present in the pseudotyped virions, but it is unlikely to be 100 %, even in a minority of the virion particles. The virions resulting from the LAC\VV co-infection probably have variable amounts of the recombinant glycoprotein on their surface and only those having a significant proportion of the antibody-resistant protein resist neutralization.
Expression of recombinant glycoproteins from a VV vector provides a straightforward method for testing the ability of these proteins to mediate binding and entry of bunyaviruses, just as pseudotyping has proven very useful in studies of retroviral biology (Landau et al., 1991 ; Salzwedel et al., 1993) . For example, Salzwedel et al. (1993) used pseudotyping to demonstrate that a glycosylphosphatidylinositol-anchored human immunodeficiency virus type 1 (HIV-1) Env protein was efficiently incorporated into HIV-1 virions but failed to mediate virus-cell fusion. Landau et al. (1991) showed that the human T-lymphotropic virus type I Env protein could alter the cellular tropism of an HIV vector by pseudotyping, and pseudotypes are used in a number of experiments examining retroviral entry.
As applied here, the technique can be extended to any glycoprotein that is resistant to an antibody that can neutralize the background virus. It can be used to examine which regions of the glycoprotein are essential and which are dispensable for binding and entry. One could also study determinants of tropism of glycoproteins from other members of the family Bunyaviridae (Griot et al., 1993 ; Pekosz et al., 1995) or unrelated viruses (Dragunova et al., 1986) . Recently, Bridgen & Elliott (1996) described a system for the generation of recombinant bunyaviruses. The technique described here may provide a useful alternative to a reverse genetic approach in instances where recombinant viruses may not be viable.
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